An updated review of the scientific literature on the origin of SARS-CoV-2

Domingo, José L.

doi:10.1016/j.envres.2022.114131

Cited by 15 publications

(9 citation statements)

References 97 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In turn, He et al (2022) tryed to answer the question “Is the virus-laden standing water change the transmission intensity of SARS-CoV-2 after precipitation?” , while Guérin-Rechdaoui et al (2022) assessed the fate of SARS-CoV-2 coronavirus in wastewater treatment sludge during storage and thermophilic anaerobic digestion. Finally, to close the present VSI, Domingo (2022) published an updated review of the scientific literature on the origin of SARS-CoV-2.…”

Section: Comments On Papers Published In the Virtual Special Issuementioning

confidence: 90%

Scientific evidence on the origin of SARS-CoV-2

Núñez‐Delgado¹,

Ahmed

Romande

et al. 2023

Environmental Research

View full text Add to dashboard Cite

Section: Comments On Papers Published In the Virtual Special Issuementioning

confidence: 90%

Scientific evidence on the origin of SARS-CoV-2

Núñez‐Delgado¹,

Ahmed

Romande

et al. 2023

Environmental Research

View full text Add to dashboard Cite

“…The animal origin of SARS-CoV-2 has been widely discussed and summarized in detail elsewhere ( Andersen et al, 2020 ; Domingo, 2021 , 2022 ; Holmes et al, 2021 ; Lytras et al, 2021 ; Shi, 2021 ; Wu et al, 2021 ), and further supported by recent progress. Temmam et al collected bat samples in northern Laos (Southeast Asia) and discovered coronaviruses including BANAL-52 in Rhinolophus malayanus , which has a higher nucleotide identity (96.8%) with SARS-CoV-2 genome, compared to the 96.1% of RaTG13 ( Temmam et al, 2022 ).…”

Section: Animal Origin Of Sars-cov-2mentioning

confidence: 94%

Updated analysis to reject the laboratory-engineering hypothesis of SARS-CoV-2

2023

Environmental Research

View full text Add to dashboard Cite

“…To date, coronavirus disease 2019 (COVID-19), a newly emerging infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has infected over 600 million people worldwide and killed over 6 million people (1,2). To control the COVID-19 epidemic and build an active immunization barrier among populations, the Chinese Government provided free COVID-19 vaccination to all citizens as of December 2020 (3).…”

Section: Introductionmentioning

confidence: 99%

Characteristics of humoral and cellular responses to coronavirus disease 2019 (COVID-19) inactivated vaccine in central China: A prospective, multicenter, longitudinal study

Yuan

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

IntroductionIn China, the long-term immunogenicity and adverse effects of inactivated vaccines produced by different or the same manufacturer remain unclear. Therefore, the objective of this study was to evaluate the cellular immune responses and neutralizing antibody kinetics of homologous and heterologous administrations of an inactivated coronavirus disease 2019 (COVID-19) vaccine 240 days after the second vaccination.MethodsThis prospective, multicenter, observational, longitudinal study involved 595 participants with a negative SARS-CoV-2 polymerase chain reaction result who were serologically tested and followed for 8 months after vaccination. Neutralizing antibodies, interferon-gamma (IFN-γ), interleukin (IL)-6, CD4+ T-lymphocyte, and B-lymphocyte counts were evaluated in serum samples after stimulation with 2 μg/mL SARS-CoV-2 spike protein for 16 h at follow-up intervals of 2 months.ResultsMost participants [582/595; 146 male participants, 449 female participants; mean age 35 (26–50 years)] rapidly developed neutralizing antibodies after two doses of the vaccine administered 3-weeks apart. The positive rate of neutralizing antibodies peaked at 97.7% at 60–90 days, decreased, and stabilized at 82.9% at 181–240 days post-vaccination. Lower antibody concentrations were correlated with older age, longer duration after vaccination, non-health care workers, mixed-manufacturer vaccinations, and intervals of less than 40 days between two doses of vaccination, whereas lower IFN-γ levels and B-lymphocyte counts were associated with older age, blood type A, and non-health care workers. A higher IL-6 level was associated with older age, mixed-manufacturer vaccinations, intervals of less than 40 days between two doses of vaccination, and medical staff. Adverse reactions were mild or moderate and self-limited, with no serious events reported.DiscussionTwo doses of the Chinese inactivated vaccine induced robust and rapid antibody expression and cellular immune responses. Boosting vaccination is considered important, as antibodies and cellular immune responses were reduced in susceptible populations.

show abstract

An updated review of the scientific literature on the origin of SARS-CoV-2

Cited by 15 publications

References 97 publications

Scientific evidence on the origin of SARS-CoV-2

Scientific evidence on the origin of SARS-CoV-2

Updated analysis to reject the laboratory-engineering hypothesis of SARS-CoV-2

Characteristics of humoral and cellular responses to coronavirus disease 2019 (COVID-19) inactivated vaccine in central China: A prospective, multicenter, longitudinal study

Contact Info

Product

Resources

About